Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Co. is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). Co. is focused on focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in clinical development following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to Alzheimer's pathology). The ABOS average annual return since 2021 is shown above.
The Average Annual Return on the ABOS average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ABOS average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ABOS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|